Trial Profile
An International, Multi-Center, Randomized, Double Blind Placebo Controlled Phase II Study to Evaluate the Safety and Efficacy of Lucanthone Administered as an Adjunct to Radiation and Temozolomide for Primary Therapy of Glioblastoma Multiforme
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 20 Oct 2021
Price :
$35
*
At a glance
- Drugs Lucanthone (Primary) ; Temozolomide
- Indications Glioblastoma
- Focus Therapeutic Use
- Sponsors Spectrum Pharmaceuticals
- 03 Apr 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 14 Feb 2013 Planned number of patients changed from 140 to 210 as reported by ClinicalTrials.gov.
- 07 Aug 2012 New source identified and integrated (Clinical Trials Registry - India),